Hpv Positively Screened Articles & Analysis: Older
8 news found
British Journal of Cancer; https://doi.org/10.1038/s41416-021-01614-4 Primary HPV screening has doubled the number of colposcopy referrals because of direct referral of HPV-positive women with ASC-US/ LSIL cytology. This study evaluated the CIN3+ risks and colposcopy referrals by QIAsure Methylation Test analysis HPV16/18 ...
This year ECCMID 2021 conference is still fully virtual, nevertheless the data presented are real! Self-screen is proud to announce that the QIAGEN NeuMoDx HPV Test Strip Assay fulfills the International Guidelines for HPV Testing, the so-called Meijer criteria. The data are presented during the QIAGEN symposium on July 12th by dr. Anja Šterbenc MD, PhD from Prof. dr. Mario Poljak’s ...
Self-screen is proud to announce the appointment of Michelle Meijer, PhD, as the companies Chief Commercial Officer. Michelle brings over 25 years of business experience in the life sciences and molecular diagnostics field, of which more than 15 years in the field of cervical cancer prevention and HPV diagnostics in particular. She held several senior business development and management roles at ...
During the QIAGEN symposium at Eurogin the latest clinical performance and study data around Self-screen’s molecular screening and triage solutions were presented by excellent scientists. Topic 31 May 2021: Full molecular screening and triage solutions, chaired by Prof. dr. Chris Meijer Presenters: Dr. Bart Hesselink (Self-screen B.V., Netherlands) – Clinical performance of ...
Self-screen’s Chief Scientific Officer dr. Bart Hesselink talks about the clinical validation of QIAGEN’s next generation HPV screening assay on the NeuMoDxTM Molecular Systems. The NeuMoDxTM 288 and NeuMoDxTM96 Molecular Systems are fully automated continuous random-access analyzers that perform adequately in standardized, high volume cervical cancer HPV screening laboratories. The ...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies. (*Complementary when referring to the US regulatory pathway.) The ...
With the introduction of HPV based screening in 2017 the Dutch cervical cancer screening program underwent an important improvement. ...
QIAGEN today announced a key allocation from the company"s "one million test" donation program to increase access to HPV screening for cervical cancer prevention among women in low-resource regions of the world. Approximately 26,000 human papillomavirus (HPV) tests will go to the Nargis Dutt Memorial Cancer Hospital for cervical cancer screening, the company said at the Women Deliver global ...